40.00
price up icon4.37%   1.675
after-market アフターアワーズ: 41.01 1.01 +2.52%
loading

Moonlake Immunotherapeutics (MLTX) 最新ニュース

pulisher
Apr 17, 2025

(MLTX) On The My Stocks Page - news.stocktradersdaily.com

Apr 17, 2025
pulisher
Apr 14, 2025

Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight - GlobeNewswire Inc.

Apr 14, 2025
pulisher
Apr 09, 2025

We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st

Apr 09, 2025
pulisher
Apr 08, 2025

Oversold Conditions For MoonLake Immunotherapeutics (MLTX) - Nasdaq

Apr 08, 2025
pulisher
Apr 08, 2025

4,500 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Purchased by KLP Kapitalforvaltning AS - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

Sei Investments Co. Acquires 1,202 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Sets New 1-Year Low – Here’s What Happened - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha

Apr 08, 2025
pulisher
Apr 07, 2025

MoonLake Immunotherapeutics’ $500 Million Debt Financing with Hercules Capital - Global Legal Chronicle

Apr 07, 2025
pulisher
Apr 04, 2025

Cantor Fitzgerald maintains Overweight on Moonlake stock - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

MoonLake secures up to $500 million financing; research update - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

Cantor Fitzgerald maintains Overweight on Moonlake stock By Investing.com - Investing.com Canada

Apr 04, 2025
pulisher
Apr 04, 2025

MoonLake secures $500m for lead drug, plus other financings - Pharmaphorum

Apr 04, 2025
pulisher
Apr 04, 2025

Switzerland: MoonLake secures up to US$500m in non-dilutive financing - Investors in Healthcare

Apr 04, 2025
pulisher
Apr 04, 2025

MoonLake in US$500m debt deal with Hercules Capital - European Biotechnology Magazine

Apr 04, 2025
pulisher
Apr 03, 2025

MoonLake secures up to $500M in financing from Hercules Capital - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake discloses up to $500M in financing; OSR’s deal with innovation fund - Endpoints News

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Obtains $500 Million Facility From Hercules Capital - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake secures hefty financing package to fuel sonelokimab's path to market - FirstWord

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Immunotherapeutics Secures $500M Financing for Growth - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Secures up to $500 Million in Non-Dilutive - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29 - Stock Titan

Apr 03, 2025
pulisher
Apr 02, 2025

MoonLake (MLTX) Secures $500M Non-Dilutive Financing to Advance Sonelokimab - GuruFocus

Apr 02, 2025
pulisher
Apr 01, 2025

How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

Teacher Retirement System of Texas Has $354,000 Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

MoonLake’s 37% decline validates InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 28, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of “Buy” from Analysts - Defense World

Mar 28, 2025
pulisher
Mar 22, 2025

Long Term Trading Analysis for (MLTX) - Stock Traders Daily

Mar 22, 2025
pulisher
Mar 20, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by PNC Financial Services Group Inc. - Defense World

Mar 20, 2025
pulisher
Mar 20, 2025

PNC Financial Services Group Inc. Increases Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - The AM Reporter

Mar 20, 2025
pulisher
Mar 19, 2025

BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com Australia

Mar 19, 2025
pulisher
Mar 19, 2025

MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Royal Bank of Canada - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha

Mar 18, 2025
pulisher
Mar 18, 2025

Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN

Mar 18, 2025
pulisher
Mar 18, 2025

Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Correction: RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $67 Price Target - MarketScreener

Mar 18, 2025
pulisher
Mar 18, 2025

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com

Mar 18, 2025
pulisher
Mar 17, 2025

MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks

Mar 17, 2025
pulisher
Mar 15, 2025

MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News

Mar 14, 2025
pulisher
Mar 14, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Sold by Victory Capital Management Inc. - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India

Mar 12, 2025
pulisher
Mar 12, 2025

MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases - TipRanks

Mar 12, 2025
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
大文字化:     |  ボリューム (24 時間):